Loperamide with simeticone
Brand names: Imodium Plus
This is a fixed-dose combination of the antimotility agent loperamide and the antifoaming agent simeticone, used for acute diarrhoea accompanied by painful gas-related abdominal symptoms such as bloating and cramping.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Loperamide acts on gut opioid receptors to slow intestinal motility and reduce stool frequency, while simeticone lowers the surface tension of gas bubbles to coalesce and disperse trapped intestinal gas, relieving bloating and flatulence.
Prescribing in practice
- As with loperamide alone, avoid in dysentery, suspected bacterial colitis with blood and fever, and active inflammatory bowel disease, where slowing motility risks serious complications including toxic megacolon.
- It is for short-term symptomatic use and does not replace oral rehydration, and the loperamide dose must not be exceeded because of the cardiac risks seen in overdose.
- Simeticone is essentially non-absorbed and inert, so the combination's cautions are driven principally by the loperamide component.
Monitoring
No routine monitoring is needed; review if symptoms persist beyond a short period or if blood, fever or abdominal distension develop.
Counselling the patient
- This combination eases both the diarrhoea and the trapped wind and bloating that can come with it.
- Keep up your fluid intake and stop and seek advice if you see blood in the stool, develop a fever, or the tummy becomes swollen.
Evidence & guidelines
The loperamide-simeticone combination is an established over-the-counter option for acute diarrhoea with associated bloating and gas.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021